Fig. 5.

Circadian rhythmicity was not altered by i.c.v. injected nesfatin-1/NucB2-neutralizing antibody (-NA). Locomotor activity (A) and core body temperature (CBT) (C) were measured by intraperitoneally implanted telemetry probe (Nanotag^®). Vehicle (8 µg/4 µL) or Nesfatin-1/NucB2-neutralizing antibody (-NA) (8 µg/4 µL) was i.c.v. administered at 30 min prior to the start of the dark cycle, at ZT 11.5. Just after the intracerebroventricular injection, Saline or CNO (1 mg/mL/kg) was subcutaneously (s.c.) administered. The measurements were commenced at ZT 0. Averaged activity (per 5 min) (B) and averaged CBT (D) were calculated every 3 h division. Data are presented as mean ± SEM (n = 5, each). *P < 0.05, **P < 0.01 vs. Saline s.c. + Vehicle i.c.v. ^#P < 0.05, ^##P < 0.01 vs. CNO s.c. + Vehicle i.c.v. E Immunohistochemical analysis of nesfatin-1/NucB2 in the suprachiasmatic nucleus (SCN)